Carlsmed (CARL) Gains from Investment Securities (2024 - 2025)
Carlsmed's (CARL) quarterly Gains from Investment Securities came in at -$7000.0 in Q4 2025, down 112.73% on a YoY basis from $55000.0 in Q4 2024, and down 110.77% quarter-over-quarter from $65000.0 in Q3 2025.
Powered by 
Analysis
Carlsmed (CARL) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Carlsmed (CARL) has reported Gains from Investment Securities for 2 consecutive years, with -$7000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 112.73% year-over-year to -$7000.0; the trailing twelve-month figure through Jun 2026 stood at $58000.0 (down 83.57% YoY), and the FY2025 full-year result was $328000.0, up 127.78% from the prior year.
- Gains from Investment Securities retreated to -$7000.0 in Q4 2025 per CARL's latest filing, from $65000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $237000.0 in Q2 2025 and bottomed at -$7000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn |
| 10 | Carlsmed | 424.72 Mn | 311.42 Mn | 14.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 61,000.00 |